Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 16, 2023, titled "Zydus receives tentative approval from the USFDA forLevomilnacipran Extended-Release Capsules".
Zydus Lifesciences Limited Press Release Jan 16 2023
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release regarding its tentative approval from the USFDA for Levomilnacipran Extended-Release Capsules. The approval allows Zydus Pharmaceuticals (USA) Inc. to market the drug, which is indicated for treating Major Depressive Disorder in adults. The capsules will be manufactured at the company's facility in Moraiya, Ahmedabad, India.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Jan 12 2023
- Press Release Jan 10 2023
- Press Release Jan 06 2023
- Press Release Dec 30 2022
- Loss of Share Certificates
Later from Zydus Lifesciences
- Press Release Jan 27 2023
- Press Release Feb 15 2023
- Zydus Lifesciences Limited Press Release Feb 17 2023
- Zydus Lifesciences Limited Press Release Feb 20 2023
- Press Release Feb 24 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences